1. Low KC and Tergaonkar V: Telomerase: Central regulator of
all of the hallmarks of cancer. Trends Biochem Sci 38: 426-434,
2013.
2. Maciejowski J and de Lange T: Telomeres in cancer: Tumour
suppression and genome instability. Nat Rev Mol Cell Biol 18:
175-186, 2017.
3. Pestana A, Vinagre J, Sobrinho-Simões M and Soares P: TERT
biology and function in cancer: Besyond immortalisation. J Mol
Endocrinol 58: R129-R146, 2017.
4. Barthel FP, Wei W, Tang M, Martinez-Ledesma E, Hu X, A m
in SB, A kdem i r KC, Seth S, Song X, Wang Q, et al: Systematic
analysis of telomere length and somatic alterations in 31 cancer
types. Nat Genet 49: 349-357, 2017.
5. Sreedevi A, Javed R and Dinesh A: Epidemiology of cervical
cancer with special focus on India. Int J Womens Health 7:
405-414, 2015.
6. Schiffman M, Wentzensen N, Wacholder S, Kinney W, Gage
JC and Castle PE: Human papillomavirus testing in the prevention
of cervical cancer. J Natl Cancer Inst 103: 368-383, 2011.
7. Cancer Genome Atlas Research Network; Albert Einstein
College of Medicine; Analytical Biological Services; Barretos
Cancer Hospital; Baylor College of Medicine; Beckman Research
Institute of City of Hope; Buck Institute for Research on Aging;
Canada’s Michael Smith Genome Sciences Centre; Harvard
Medical School; Helen F. Graham Cancer Center & Research
Institute at Christiana Care Health Services, et al: Integrated
genomic and molecular characterization of cervical cancer. Nature
543: 378-384, 2017.
8. Khurana E, Fu Y, Chakravarty D, Demichelis F, Rubin MA and
Gerstein M: Role of non-coding sequence variants in cancer. Nat
Rev Genet 17: 93-108, 2016.
9. Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A,
Kadel S, Moll I, Nagore E, Hemminki K, et al: TERT promoter
mutations in familial and sporadic melanoma. Science 339:
959-961, 2013.
10. Liu X, Bishop J, Shan Y, Pai S, Liu D, Murugan AK, Sun
H, El-Naggar AK and Xing M: Highly prevalent TERT promoter
mutations in aggressive thyroid cancers. Endocr Relat Cancer 20:
603-610, 2013.
11. Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz
LA Jr, Friedman AH, Friedman H, Gallia GL, Giovanella BC, et
al: TERT promoter mutations occur frequently in gliomas and a
subset of tumors derived from cells with low rates of self-renewal.
Proc Natl Acad Sci USA 110: 6021-6026, 2013.
12. Vinothkumar V, Arunkumar G, Revathidevi S, Arun K,
Manikandan M, Rao AK, Rajkumar KS, Ajay C, Rajaraman R,
Ramani R, et al: TERT promoter hot spot mutations are frequent
in Indian cervical and oral squamous cell carcinomas. Tumour
Biol 37: 7907-7913, 2016.
13. Park CK, Lee SH, Kim JY, Kim JE, Kim TM, Lee ST, Choi SH,
Park SH and Kim IH: Expression level of hTERT is regulated by
somatic mutation and common single nucleotide polymorphism at
promoter region in glioblastoma. Oncotarget 5: 3399-3407, 2014.
14. Spiegl-Kreinecker S, Lotsch D, Ghanim B, Pirker C, Mohr
T, Laaber M, Weis S, Olschowski A, Webersinke G, Pichler J
and Berger W: Prognostic quality of activating TERT promoter
mutations in glioblastoma: Interaction with the rs2853669
polymorphism and patient age at diagnosis. Neuro Oncol 17:
1231-1240, 2015.
15. Mosrati MA, Malmström A, Lysiak M, Krysztofiak A,
Hallbeck M, Milos P, Hallbeck AL, Bratthäll C, Strandéus
M, Stenmark-Askmalm M and Söderkvist P: TERT promoter
mutations and polymorphisms as prognostic factors in primary
glioblastoma. Oncotarget 6: 16663-16673, 2015.
16. Ko E, Seo HW, Jung ES, Kim BH and Jung G: The TERT
promoter SNP rs2853669 decreases E2F1 transcription factor
binding and increases mortality and recurrence risks in liver
cancer. Oncotarget 7: 684-699, 2016.